You evaluation of the PARACHUTE-HF trial: role of sacubitril/valsartan compared to enalapril on outcomes in patients with heart failure from Chagas' disease.

Dmitry Abramov, Abdul Mannan Khan Minhas, Tamas Alexy, Patricia Oliveira Guimaraes, Mitja Lainscak, Peder L Myhre

Abstract readReview

In one paragraph

Review in Heart failure reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dmitry AbramovDivision of Cardiology, Loma Linda University Health, Loma Linda, CA, USA. Dabramov@llu.edu.

Abdul Mannan Khan MinhasSection of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

Tamas AlexyDepartment of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, USA.

Patricia Oliveira GuimaraesHospital Israelita Albert Einstein, São Paulo, Brazil.

Mitja LainscakFaculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Peder L MyhreDepartment of Cardiology, Akershus University Hospital, Lørenskog, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure is a common manifestation of Chagas’ disease and results in significant morbidity and mortality in affected patients. In light of limited data on therapeutic options for heart failure due to Chagas’ disease, the PARACHUTE-HF trial aimed to compare the effects of sacubitril/valsartan versus enalapril on clinical endpoints and changes in natriuretic peptides in this population. This mini-review contextualizes the results of the trial, which demonstrated that sacubitril/valsartan led to significant improvements in outcomes driven primarily by a reduction in natriuretic peptides.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsChagas CardiomyopathyChagas DiseaseEnalaprilHeart FailureTetrazolesAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsDrug CombinationsHumansRandomized Controlled Trials as TopicTreatment OutcomeValsartanAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsEnalaprilsacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanChagas cardiomyopathyChagas diseaseHeart failureSacubitril/valsartan

Identifiers

PMID41910669

DOI10.1007/s10741-026-10617-3

PMCPMC13035569

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.